- Cassava Sciences (SAVA, Financial) appoints Dr. Angélique Bordey as Senior Vice President of Neuroscience.
- Dr. Bordey's research has led to a new patent for simufilam in treating TSC-related epilepsy.
- License agreement secured with Yale University (Trades, Portfolio) to explore simufilam's potential indication.
Cassava Sciences, Inc. (NASDAQ: SAVA), a clinical-stage biotechnology company based in Austin, Texas, has announced the appointment of Dr. Angélique Bordey as Senior Vice President (SVP) of Neuroscience. In her new role, Dr. Bordey will lead the company's research and development efforts focused on evaluating simufilam as a potential treatment for tuberous sclerosis complex (TSC)-related epilepsy. Despite her new role, she will continue her duties part-time as Vice Chair of the Department of Neurosurgery at Yale School of Medicine.
Dr. Bordey's scientific research has been instrumental in Cassava Sciences' recent patent approval, which covers the use of simufilam to treat TSC-related epilepsy. The company has secured a license agreement with Yale University (Trades, Portfolio), which may open avenues for further exploration of simufilam in this indication. With over 125 academic publications to her name, Dr. Bordey's expertise is expected to advance Cassava's preclinical program significantly and enable productive collaborations within the study community.
TSC-related epilepsy is a challenging syndrome that often requires innovative treatment solutions. Cassava Sciences aims to leverage simufilam's unique mechanism of action to provide new treatment options for this rare disease. Dr. Bordey's leadership and reputation in the TSC community are expected to facilitate progress in this area.
